Phase IV study of tailored therapy with peg interferon alfa 2b and ribavirin for patients with genotype 3 and high viral load. Genotype 3 extended treatment for HCV (GET-C study).
Phase of Trial: Phase IV
Latest Information Update: 26 Jun 2014
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms GET-C
- Sponsors Schering-Plough
- 28 Jul 2009 Actual patient number (146) added as reported by ClinicalTrials.gov.
- 21 Mar 2008 Status change from suspended to discontinued, as reported by clinicaltrials.gov.
- 17 Jan 2008 The expected completion date for this trial is now 1 Aug 2008 as reported by ClinicalTrials.gov.